Is Arch Biopartners Inc. (ACHFF) a Buy, Sell, or Hold?
OTC : ACHFF
Arch Biopartners Inc. — News
$0.82 USD
$0.09 (11.79%)
- Volume
- 12.9K
- Average Volume
- 27.21K
- Market Capitalization
- $55.71M
- P/E Ratio
- -29.85
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.27
- Year Low
- $0.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.11
| Source | Headline |
|---|---|
|
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company's pre-IND IL-32 chronic kidney disease (“CKD”) program. globenewswire.com - 2026-07-17 08:20:00 |
|
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. globenewswire.com - 2026-07-08 02:00:00 |
|
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the 2026 American Diabetes Association Thought Leadership Series at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films. globenewswire.com - 2026-06-04 07:41:00 |
|
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company's ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS). globenewswire.com - 2026-05-22 06:50:00 |
